| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 126 | 136 | 102 | 105 | 118 | 119 | 81 | 100 | 114 | 131 | 150 | 173 | 164 | 176 | 123 | 61 | 65 | 160 | 151 | 151 | 136 | 167 | 163 | 248 | 166 | 198 | 176 | 250 | 197 |
| Expenses | 101 | 110 | 76 | 88 | 94 | 96 | 60 | 82 | 91 | 107 | 114 | 130 | 119 | 128 | 94 | 65 | 65 | 146 | 130 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 |
| EBITDA | 24 | 27 | 26 | 16 | 24 | 23 | 21 | 18 | 22 | 25 | 35 | 42 | 46 | 48 | 29 | -4 | 0 | 14 | 21 | 25 | 27 | 29 | 31 | 35 | 35 | 33 | 35 | 42 | 40 |
| Operating Profit % | 19 % | 19 % | 25 % | 15 % | 20 % | 19 % | 25 % | 15 % | 19 % | 18 % | 23 % | 24 % | 27 % | 27 % | 22 % | -7 % | -1 % | 9 % | 12 % | 16 % | 19 % | 17 % | 18 % | 14 % | 20 % | 16 % | 19 % | 16 % | 20 % |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 | 4 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 |
| Profit Before Tax | 16 | 19 | 19 | 8 | 15 | 14 | 13 | 9 | 14 | 16 | 27 | 34 | 33 | 35 | 16 | -16 | -13 | 1 | 7 | 11 | 13 | 15 | 17 | 22 | 22 | 20 | 22 | 29 | 24 |
| Tax | 9 | 9 | 9 | -5 | 8 | 5 | 5 | 2 | 7 | 5 | 5 | 11 | 9 | 12 | 7 | -23 | 0 | 3 | 3 | 4 | 3 | 3 | 5 | 5 | 5 | 5 | 4 | 8 | 4 |
| Net Profit | 7 | 10 | 9 | 13 | 8 | 10 | 8 | 6 | 7 | 11 | 21 | 23 | 24 | 23 | 9 | 6 | -13 | -2 | 4 | 6 | 9 | 12 | 12 | 17 | 17 | 14 | 18 | 20 | 21 |
| EPS in ₹ | 0.85 | 1.19 | 1.11 | 1.57 | 0.92 | 1.17 | 0.90 | 0.76 | 0.83 | 1.30 | 2.53 | 2.73 | 2.78 | 2.72 | 1.07 | 0.73 | -1.51 | -0.24 | 0.44 | 0.73 | 1.10 | 1.39 | 1.36 | 2.04 | 1.95 | 1.67 | 2.15 | 2.40 | 2.31 |
SMS Pharmaceuticals
SMS Pharmaceuticals
235.30
+0.58
(0.25%)
Market Cap
2,085.98 Cr
EPS
8.16
PE Ratio
28.44
Dividend Yield
0.17 %
Industry
Healthcare52 Week High
398.00
52 Week Low
176.05
PB Ratio
3.25
Debt to Equity
0.54
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
SMS Pharmaceuticals Reports Monitoring Agency Update on Rs 114.30 Crore Warrant Issue Proceeds3 days ago
SMS Pharmaceuticals Limited submitted a monitoring agency report from CARE Ratings Limited regarding the utilization of proceeds from their preferential issue of convertible warrants for the quarter ended June 30, 2025. The company raised Rs 114.30 crore through a private placement of convertible share warrants issued between March 7-13, 2024. The funds were allocated for capital expenditure (Rs 62.87 crore), working capital (Rs 40.00 crore), and general corporate purposes (Rs 11.43 crore). As of June 2025, Rs 28.57 crore has been utilized with Rs 17.14 crore for capital expenditure and Rs 11.43 crore for working capital requirements. The company temporarily deployed Rs 38.10 crore towards working capital needs, including Rs 27.10 crore to repay working capital demand loans and Rs 10.41 crore for reducing outstanding working capital balances. CARE Ratings reported no deviations from the stated objects and confirmed all utilization was as per the offer document. The monitoring agency noted that any delay in raising balance funds may impact completion of proposed capital expenditure, though promoters are willing to infuse funds as required within the given timeline.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.30 | #1 3,91,403.51 | 34.36 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 46.65 | |
6,186.00 | 1,64,218.86 | 70.57 | 9,712.00 | 18.67 | 2,191 | 26.74 | 37.51 | |
1,565.40 | 1,26,438.58 | 23.42 | 28,409.50 | 7.12 | 5,291 | 9.88 | 62.75 | |
3,631.10 | 1,22,892.92 | 60.70 | 11,539.40 | 6.99 | 1,911 | 19.91 | 57.93 | |
1,256.60 | 1,04,872.20 | #1 18.50 | 33,741.20 | 16.73 | 5,725 | 1.26 | 53.20 | |
2,465.00 | 1,01,737.64 | 53.98 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.22 | |
982.80 | 98,892.68 | 21.34 | 23,511.00 | 18.55 | 4,615 | 2.60 | 57.97 | |
1,969.50 | 89,946.17 | 24.20 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 53.80 | |
32,680.00 | 69,442.72 | 48.63 | 6,684.70 | 9.64 | 1,414 | 11.55 | 48.48 | |
5,354.00 | 64,015.10 | 28.11 | 13,458.30 | 3.70 | 2,216 | 21.39 | 68.13 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
35.43 %
Net Income Growth
1,161.54 %
Cash Flow Change
123.25 %
ROE
991.67 %
ROCE
192.43 %
EBITDA Margin (Avg.)
50.49 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Fixed Assets | 370 | 291 | 279 | 281 | 281 | 457 | 438 | 412 | 437 | 568 |
| Current Assets | 248 | 157 | 169 | 208 | 219 | 309 | 377 | 411 | 534 | 555 |
| Capital Work in Progress | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 |
| Investments | 0 | 29 | 28 | 27 | 26 | 27 | 22 | 11 | 11 | 285 |
| Other Assets | 272 | 166 | 187 | 232 | 260 | 321 | 389 | 424 | 556 | 0 |
| Total Liabilities | 656 | 493 | 503 | 559 | 608 | 812 | 860 | 880 | 1,034 | 1,153 |
| Current Liabilities | 200 | 147 | 122 | 143 | 145 | 195 | 197 | 255 | 332 | 324 |
| Non Current Liabilities | 162 | 91 | 97 | 94 | 115 | 206 | 193 | 164 | 166 | 189 |
| Total Equity | 294 | 255 | 285 | 322 | 348 | 411 | 470 | 461 | 536 | 640 |
| Reserve & Surplus | 285 | 246 | 276 | 314 | 340 | 402 | 462 | 452 | 499 | 631 |
| Share Capital | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Cash Flow
| Cash Flow | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -9 | 1 | 0 | 2 | -5 | 31 | 6 | -39 | 29 |
| Investing Activities | -97 | -39 | -17 | -35 | -43 | -152 | -27 | -30 | -52 |
| Operating Activities | 61 | 74 | 32 | 50 | 40 | 90 | 45 | 23 | 50 |
| Financing Activities | 27 | -33 | -15 | -13 | -2 | 92 | -12 | -32 | 31 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 67.29 % | 64.17 % | 64.17 % | 64.17 % | 64.29 % | 64.32 % | 64.32 % | 64.32 % | 64.67 % | 64.67 % | 64.67 % | 64.67 % | 66.26 % | 66.26 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.60 % | 0.59 % | 0.17 % | 0.17 % | 0.52 % | 0.31 % | 0.08 % | 0.03 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 1.98 % | 2.13 % | 2.55 % | 2.55 % | 2.43 % | 3.03 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 26.92 % | 26.87 % | 26.23 % | 26.72 % | 26.38 % | 29.65 % | 28.84 % | 28.82 % | 29.00 % | 29.04 % | 29.08 % | 29.22 % | 27.93 % | 27.81 % | 27.04 % | 27.38 % | 26.35 % | 25.89 % |
| Others | 5.79 % | 5.84 % | 6.47 % | 5.99 % | 6.33 % | 6.18 % | 6.98 % | 7.00 % | 6.70 % | 6.64 % | 6.01 % | 5.88 % | 5.25 % | 5.22 % | 5.23 % | 5.09 % | 4.87 % | 4.78 % |
| No of Share Holders | 19,878 | 25,601 | 24,608 | 24,959 | 27,516 | 26,638 | 26,491 | 26,526 | 25,537 | 24,653 | 25,246 | 25,341 | 30,140 | 31,780 | 33,136 | 34,973 | 35,332 | 33,652 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.2 | 0.25 | 0.25 | 0.25 | 0.3 | 0.3 | 0.3 | 0.4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.27 | 0.4 | 0.93 | 0.2 | 0.32 | 0.53 | 0.17 | 0.19 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 29 Sept 2025 |  Annual General Meeting | NA | 29 Sept 2025 | 223.95 | 234.60 |
| 22 Sept 2025 |  Dividend | ₹ 0.40 /share | 22 Sept 2025 | 270.37 | 234.60 |
| 09 Aug 2025 |  Quarterly Result Announcement | NA | 09 Aug 2025 | 228.91 | 223.95 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 262.50 | 270.37 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 205.15 | 200.02 |
| 08 Nov 2024 | Quarterly Result Announcement | NA | 08 Nov 2024 | 294.60 | 305.90 |
| 30 Sept 2024 | Annual General Meeting | NA | 30 Sept 2024 | 312.55 | 351.20 |
| 23 Sept 2024 | Dividend | ₹ 0.40 /share | 23 Sept 2024 | 209.90 | 368.65 |
| 06 Mar 2024 |  Extraordinary General Meeting | NA | 06 Mar 2024 | 146.45 | 181.90 |
| 22 Sept 2023 | Dividend | ₹ 0.30 /share | 22 Sept 2023 | 84.40 | 121.50 |
| 23 Sept 2022 | Dividend | ₹ 0.30 /share | 22 Sept 2022 | 84.35 | 89.80 |
| 24 Sept 2021 | Dividend | ₹ 0.30 /share | 22 Sept 2021 | 167.60 | 157.70 |
Announcements
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication7 days ago
7 days agoInvestor Presentation On Financial Results7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoResults For The Quarter Ended June 30 20258 days ago
8 days agoRecord Date For The Purpose Of Determining The Members Eligible To Receive Dividend For The Financial Year 2024-258 days ago
8 days agoStatement Of Deviation Or Variation For The Quarter Ended June 30 20259 days ago
9 days agoBoard Meeting Outcome for Outcome Of Board Meeting And Financial Results9 days ago
9 days agoBoard Meeting Intimation for Unaudited (Standalone And Consolidated) Financial Results For The First Quarter Ended On 30Th June 2025Aug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Intimation Under Regulation 30 Of SEBI LODR Regulations 2015 - Reminder Letter For Transfer Of Shares To Investor Education And Protection Fund (IEPF)Jul 08, 2025
Jul 08, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 01, 2025
Jul 01, 2025Board Meeting Outcome for Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jul 01, 2025
Jul 01, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 30, 2025
Jun 30, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jun 30, 2025
Jun 30, 2025Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jun 30, 2025
Jun 30, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 30, 2025
Jun 30, 2025Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.Jun 30, 2025
Jun 30, 2025Announcement Under Regulation 30 (LODR) - Investments In Subsidiary Company By Way Of Subscription Towards Rights IssueJun 27, 2025
Jun 27, 2025Disclosure Under Regulation 30 Of SEBI LODR RegulationsJun 26, 2025
Jun 26, 2025Successful Completion Of USFDA Inspection At SMS Pharmaceuticals LimitedS Central Laboratory Analytical ServicesJun 25, 2025
Jun 25, 2025Intimation Of Receipt Of Trading Approval From Stock ExchangesJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Report On Statement Of Deviation For The Quarter Ended March 31 2025May 30, 2025
May 30, 2025Please Find AnnexureMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 30, 2025
May 30, 2025Financial Results For The Fourth Quarter And Year Ended 31St March 2025May 30, 2025
May 30, 2025Board Meeting Outcome for Outcome Of The Board Meeting - Financial Results For The Fourth Quarter And Year Ended 31St March 2025.May 30, 2025
May 30, 2025Technical Indicators
RSI(14)
Neutral 50.93
ATR(14)
Less Volatile 8.51
STOCH(9,6)
Neutral 63.04
STOCH RSI(14)
Overbought 98.01
MACD(12,26)
Bullish 0.83
ADX(14)
Weak Trend 23.05
UO(9)
Bearish 54.35
ROC(12)
Downtrend And Accelerating -0.96
WillR(14)
Neutral -23.21
Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Quant Small Cap Fund Direct Plan-Growth | 0.15% | 5032 | -0.01% | -0.02% | |
 Bandhan BSE Healthcare Index Fund Direct-Growth | 0.05% | -15 | 0.00% | -0.01% | |
| Quant Healthcare Fund Direct - Growth | 4.77% | 0 | -0.14% | -0.52% |
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
